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Introduction
The prognosis of patients with systemic lupus erythemato-
sus (SLE) has improved significantly over the past two
decades [1]. Earlier diagnosis on the basis of better
awareness, description of new autoantibody specificities,
and improvement of serological techniques may have sup-
ported this development. However, the introduction of
pulse cyclophosphamide therapy for lupus nephritis [2] as
well as advances in hemodialysis techniques were pivotal
for this improvement, since it was irreversible renal failure
and its consequences that previously had a high impact
on mortality [3]. Nevertheless, almost 10% of SLE patients
still die within the first 5 years of their disease and their
mean life expectancy is significantly shorter than in the
general population, due partly to relentlessly progressive
lupus in some patients and partly to sequelae of treatment,
particularly those of cytotoxic agents and glucocorticoids
[4,5]. This situation calls for the search for new therapeu-
tic strategies with higher efficacy and lesser comorbidity.
SLE is the prototype non-organ-specific autoimmune
disease. A multisystem disorder, it destroys cells and
organs by means of autoantibodies and immune com-
plexes. The mechanisms underlying the hyper-reactivity and
autoreactivity of the immune system in SLE are unknown. A
setting of genetic susceptibility involving multiple genes [6]
in conjunction with environmental triggers constitutes the
hypothetical etiopathogenic background. As long as the
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triggers of the disease are unknown, novel therapeutic
approaches must be aimed mainly at interference with the
generation of autoantibodies and immune complexes or
with their consequences, namely cell destruction and
inflammation. In this review, some of the many potential
future therapeutic approaches are discussed. Further infor-
mation is included in a recent textbook chapter [7].
Is there a potential for causative treatment?
The role of infectious triggers of autoimmune diseases has
been debated for decades. The earliest evidence pointing
to such associations stems from acute rheumatic fever
induced by streptococcal infections and the subsequent
generation of antistreptococcal antibodies, which cross-
react with cardiac tissue and lead to rheumatic heart
disease in susceptible individuals [8]. Type I diabetes has
been often linked to Coxsackie virus infections [9]; some
forms of vasculitis appear to be a consequence of infec-
tion with hepatitis B or C virus [10]; and peptide
sequences of a variety of SLE-related autoantigens are
homologous to sequences of various viral proteins
[11–14]. In fact, a peptide of the Sm protein, which can
elicit a variety of autoantibodies and experimental lupus in
an immunized animal, has homologies with a protein
present on Epstein–Barr virus (EBV) [15,16].
In contrast to the earlier, unsupported hypotheses, there is
at least some recent important epidemiological evidence
that SLE may be associated with EBV infection [16]. EBV
is a common infection worldwide. In the African regions,
EBV infection is commonly associated with a variety of
malignancies [17]. In these regions, SLE is rare [18]. On
the other hand, in the industrialized world, people of African
origin have a high risk of developing SLE [18], while EBV-
associated malignancies are rare in those regions. Thus, it
is conceivable that under different environmental circum-
stances EBV may induce different diseases or be, at least,
a cofactor in the pathogenesis of different disorders, one of
them SLE. Importantly, as EBV is one cause of lymphomas
in the industrialized world [17] and is usually contracted
during adolescence, one wonders if the design of a
vaccine protecting against EBV infection and given in early
childhood would reduce the risk not only of such malignan-
cies, but also of SLE.
Induction of tolerance
Autoimmune diseases are often considered to be a conse-
quence of lost tolerance to self-antigens. Whether this is
truly the case or there are other pathways responsible for
the evolution of a pathogenic autoimmune response,
induction of unresponsiveness and reversal of the respec-
tive immune response might constitute an interesting and
successful therapeutic approach.
Given that some of the presumably most pathogenic types
of autoantibodies in SLE are directed to dsDNA, down-
modulation of their production is one important therapeu-
tic aim. In experimental animals, a compound containing
four oligonucleotides on a triethylene glycol backbone
(LJP 394) is capable of downmodulating anti-dsDNA pro-
duction, presumably by cross-linking the specific antigen
receptor on the surface of the B cell. This approach led to
amelioration of disease and higher survival in mice with
lupus [19]. Anti-dsDNA was also reduced in patients with
SLE who were treated with LJP 394 [20]. Phase II/III ran-
domized controlled trials are now under way.
In patients with autoimmune diseases, autoantibodies are
usually of the IgG class and have hypermutated V region
genes in comparison with the germ line. This clearly sug-
gests the involvement of T-cell help. In fact, T cells incu-
bated with nucleosomes or histones in both experimental
and human SLE support the production of anti-dsDNA by B
cells [21,22]. Since autoimmunity directed towards histone
H1 appears to be of pivotal importance in SLE [23], induc-
tion of tolerance to nucleosomal antigens may be an inter-
esting approach; it has already been successfully applied in
experimental models [24]. Moreover, activation of ‘suppres-
sor’ T cells, which more than two decades ago were found
to be defective in SLE [25] and have conceptually re-
emerged more recently as ‘regulatory’ T cells [26], may be
an interesting new therapeutic approach for the induction of
unresponsiveness. Moreover, since interaction of CTLA-4
with its ligand CD80/86 interrupts the costimulatory path-
ways needed to activate T cells [27], application of a CTLA-
4–IgG fusion protein may interfere with the immunologic
processes involved in disease induction in mice and man
[28,29] and lead to tolerance. Similar effects may be seen
with antibodies to CD80/86 (B7.1 and 2) [30].
Tolerance may also be achieved by active immunization
with tolerizing peptides and a reduction of autoantibody
production has been observed experimentally when pep-
tides from anti-dsDNA antibodies were used [31].
Prevention of the consequences of
pathogenic autoantibody production
The mere presence of autoantibodies is not necessarily
associated with disease. On the one hand, nonpathogenic
autoimmunity is part of our ‘normal’ immunologic reper-
toire [32]; on the other hand, the pathogenicity of autoanti-
bodies and the consequent immune complexes is mostly
brought about by the activation of complement and the
interaction with cell-membrane-bound Fc receptors. Thus,
interference with the complement pathways, as in knock-
out mice or when specific antibodies are used, can
prevent or ameliorate lupus [33,34]. Soluble complement
receptors may also be beneficial [35]. Likewise, interfer-
ence with the IgG Fcγ receptor (FcγR) interaction, as in
FcγR I/III knockout mice or when anti-CD16 antibodies are
used, can prevent the evolution of clinical manifestations
of the disease [36,37]. On the other hand, activation ofS27
inhibitory FcγRs which contain an immunoreceptor tyro-
sine inhibitory motif (ITIM), in contrast with the immunore-
ceptor tyrosine activation motif (ITAM) of other FcγRs
[38], may downmodulate B-cell function when co-cross-
linked with the B cell’s antigen receptor. Such FcγR-medi-
ated inhibition of B-cell activity may not only be induced by
immune complexes that carry an antigen binding to the
surface immunoglobulin of the B cell while the immuno-
globulin moiety of the immune complex engages the
FcγRIIb, but also by intravenous immunoglobulin [39].
There are reports of the efficacy of intravenous
immunoglobulin in SLE [40], although further confirmation
is awaited. The importance of FcγRs as potential thera-
peutic targets is also supported by reports on genetic
linkage of SLE with a region on chromosome 1 that
encodes the FcγRs [41].
The interventions discussed above were all directed at the
consequences of immune complex production. However,
considering autoantibody production, pathogenicity may
also be prevented by interfering with autoantibody binding
to the (auto)antigen or by eliminating the already bound
autoantigen. The latter approach was not blessed with
clinical efficacy, since the application of recombinant
DNase, aiming at eliminating DNA from the respective
immune complexes, had no clinical effects [42]. In con-
trast, the application of heparin, which prevents the
binding of circulating charged nucleosomal antigens to
the glomerular basement membrane, prevented the occur-
rence of nephritis in experimental lupus and possibly
should constitute an adjunctive therapy in patients with
lupus nephritis [43]. Another interesting means is to dis-
place the antigen in the pathogenic immune complex with
cross-reactive peptides. In one study, such an approach
using peptides containing D-amino acids prevented
glomerular deposition [44].
Interference with the cytokine network and
signal transduction
Although the debate whether SLE is primarily a Th1- or a
Th2-mediated disease is still unresolved, cytokines appear
to play important roles both in human and murine lupus.
Not only has IFN-γ been found to be highly increased in
sera of patients with lupus [45], but therapy with this
cytokine has led to activation and induction of SLE
[46,47]. The value of IFN-γ as a therapeutic target is sup-
ported by the fact that IFN-γ knockout lupus-prone mice
do not develop the disease; moreover, treatment of experi-
mental SLE with IFN-γ receptors inhibits lupus nephritis
[48–51]. All these notions are further supported by the
observation of an amelioration of experimental lupus by the
prototypic Th2 cytokine IL-4 [52].
While the lymphokines mentioned above play important
roles in the generation of the primary immune response
and its skewing towards specific reactivity patterns [53],
the proinflammatory cytokines are significantly involved in
tissue destruction. The central proinflammatory cytokines,
tumor necrosis factor (TNF)-α and IL-1, are increased in
SLE and can both be activated by immune complexes
[54–56]. Moreover, we have recently observed significant
amounts of TNF-α by immunohistochemistry in renal biop-
sies from patients with lupus nephritis (manuscript in
preparation). Nevertheless, the role of TNF-α is currently
under intensive discussion. On the one hand, in experi-
mental animals, TNF can induce nephritis and TNF-α defi-
ciency ameliorates nephritis [57,58]; on the other hand,
injection of TNF-α can ameliorate murine SLE under
certain circumstances [59]. This latter observation in con-
junction with an occasional appearance of a lupus-like
syndrome in patients with rheumatoid arthritis (RA) who
are treated with TNF blockers [60] has led to the sugges-
tion that TNF may be protective in lupus and that inhibition
of TNF may therefore be potentially detrimental. However,
not only are these events rare and, as of now, no more
commonly observed than similar drug-induced lupus syn-
dromes during many other therapies used for RA [61,62],
but also the anti-dsDNA autoantibodies observed among
patients treated with TNF blocker are not consistently
observed and are usually of the IgM rather than a patho-
genic IgG isotype [63,64].
To account for all these findings, my colleagues and I have
proposed that TNF may play a dual role in SLE. This
cytokine could well interfere with the regulation of the
immune response and lead to an increase of autoantibody
production; however, it may also have a critical role in the
final pathway of SLE disease, namely immunologically
induced and inflammation-induced tissue destruction.
Thus, inhibition of TNF-α may, in fact, be a highly valuable
tool in patients with active SLE, while inhibition of a poten-
tial autoantibody-enhancing activity could be achieved by
concomitant immunosuppressive agents. The rapid inter-
ference of TNF blockers with the inflammatory response
[65] suggests that they may be very beneficial for patients
with active lupus nephritis and possibly other SLE mani-
festations [66,67]. Support for the efficacy and safety of
TNF blockade in connective tissue disease stems from
observations in patients with RA/SLE overlap (D Furst,
personal communication) and individual cases of patients
with mixed connective tissue disease ([68] and unpub-
lished observations). My colleagues and I are currently
embarking on a small clinical trial with Ethical Committee
approval to address the potential of TNF blockade to ame-
liorate SLE.
Targeting signal transduction pathways
Proinflammatory cytokines and lymphokines mediate their
effects by activating transcription factors via diverse signal
transduction mechanisms induced after receptor ligation.
Among the most important pathways are those involving
mitogen-activated protein kinases (MAPKs) and nuclear
Available online http://arthritis-research.com/content/4/S3/S025S28
factor (NF)-κB as well as the Janus kinases (JAKs). Inter-
ference with these pathways can ameliorate inflammatory
diseases. One compound already approved for RA,
leflunomide, interferes with NFκB activation [69] and also
has some beneficial effects on mild SLE [70,71]. Many
other drugs are currently in development and may have a
potential as future therapeutic agents [72,73].
Stem cell therapy
The use of myeloablative cytotoxic therapy to combat the
immunoinflammatory insult, with subsequent stem cell
rescue to replenish the hematopoietic system and recon-
stitute the immune system, may be an attractive way of
treating aggressive forms of SLE. Autologous stem cell
therapy has been performed in small series of patients in
recent years with some success [74], and we ourselves
also had successful results in relentlessly progressive, life-
threatening SLE [75].
Conclusion
In summary, rescue from organ failure and survival of
patients with SLE need to be further improved. Advances
in immunology and molecular biology have provided new
therapeutic targets and new tools for potential treatment
success. It will be important to study such new therapies
using thoroughly designed protocols [76], but clearly
there is hope for even better remedies than are available
today and possibly cure of the disease.
Glossary of terms
CTLA-4 = cytotoxic T-lymphocyte antigen 4.
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